Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

blank

 

Recent News and Articles on the Keywords: fda expected + heartburn drug + drug  Related to the article below (Last Update: 5/13/2008)

Wyeth Recovers From Its Heartburn
Motley Fool - Apr 23, 2008
Next week the company should hear back from the FDA about its opioid-induced constipation (OIC) drug, which it will market with Progenics Pharmaceuticals' ...
2nd UPDATE: Wyeth 1Q Net Slips 4.6% As Protonix Sales Plunge CNNMoney.com
all 141 news articles »  WYE
3rd UPDATE: Merck 1Q Net Nearly Doubles On AstraZeneca Gain
CNNMoney.com - Apr 21, 2008
Under their longstanding partnership, Merck shares in the proceeds of certain products marketed by AstraZeneca , including the blockbuster heartburn drug ...MRK - AZN
Wyeth wields the axe again
OutSourcing-Pharma.com, UK - May 2, 2008
Since the beginning of 2007, the US Food and Drug Administration (FDA) has delayed granting regulatory approval for Wyeth's schizophrenia drug bifeprunox; ...
Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal ...
MSN Money - May 6, 2008
On December 28, 2007, Perrigo announced it received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for OTC Cetirizine ...PRGO
Business Highlights
CNNMoney.com - Apr 21, 2008
Merck (NYSE:MRK) said its profit nearly doubled in the first quarter because of a $1.4 billion distribution from a partner drug company and a slight rise in ...

In order to show you the most relevant results, we have omitted some entries very similar to the 5 already displayed.
If you like, you can repeat the search with the omitted results included.

Source: Google News

Adverse drug event monitoring at the food and drug administration -
SR Ahmad - Journal of General Internal Medicine, 2003 - Springer
... diabetes drug troglitazone and the heartburn drug cisapride are ... visiting the FDA's
website (www.fda.gov/medwatch ... Comparison of reported and expected deaths in ...

Information, Marketing, and Pricing in the US Antiulcer Drug Market -
ER Berndt, L Bui, D Reiley, G Urban - American Economic Review, 1995 - JSTOR
... marginal prices, etc.) cannot be expected to describe ... ditions (indications) for which
the FDA has granted ... condition that ranges from modest heartburn and acid ...

the management of heartburn in pregnancy. -
JE RICHTER - Alimentary Pharmacology & Therapeutics, 2005 - pt.wkhealth.com
... higher frequency of remission of heartburn and regurgitation ... were observed, whereas
eight were expected.16 Therefore, sucralfate is an FDA category B ...

Direct-to-Consumer Prescription Drug Advertising and the Public -
RA Bell, RL Kravitz, MS Wilkes - J Gen Intern Med, 1999 - Blackwell Synergy
... We expected to find greater influence among ... cholesterol level (Pravachol); severe
heartburn (Prilosec); depression ... overestimate the extent of FDA oversight of ...

[CITATION] FDA Approves Over-Counter Sales of Top Ulcer Drug
G Harris - New York Times

Changing a drug from Rx to OTC status: the consumer behavior and public policy implications of … -
EH Creyer, I Hrsistodoulakis, CA Cole - Journal of Product and Brand Management, 2001 - ingentaconnect.com
... As expected, elderly consumers were more likely than younger ... to self- medicate symptoms
of heartburn and indigestion. ... the importance of the FDA's initiative to ...

Direct-to-Consumer Prescription Drug Advertising: Content Analysis and Public Policy Implications
BJ Parker, LM Delene - Journal of Pharmaceutical Marketing & Management, 1998 - haworthpress.com
... more stringent standard by the FDA and must ... It was expected that the percentage of
ads ... Depression Epilepsy Hair loss Heartburn Hypertensiordangina Hypertension ...

To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs -
ER Berndt - New England Journal of Medicine, 2005 - content.nejm.org
... use of medications, they can be expected to demand ... is sub- ject to FDA regulation,
including ... Allergies Depression Hypertension Pain Heartburn High Cholesterol ...

Incorporating the Patient's Perspective into Drug Development and Communication: An Ad Hoc Task … -
C Acquadro, R Berzon, D Dubois, NK Leidy, P … - Value in Health, 2003 - Blackwell Synergy
... to open a dialogue between the FDA and organizations ... In contrast, an assessment of
heartburn-related symptom ... by 2050, those percentages are expected to rise to ...

Now Available without a Prescription.
T Nordenberg - FDA Consumer, 1996 - questia.com
... hydrochloride@, and Axid AR (nizatidine), for heartburn, and Rogaine ... was told that
abuse was not expected to be ... FDA agreed that the benefits of the patch - an ...

Source: Google Scholar

FDA update on AstraZeneca heartburn drugs expected

WASHINGTON - U.S. regulators are likely to update the public within days about any potential heart risks of AstraZeneca Plc's stomach-acid drugs, which are taken by more than 1 billion people worldwide.

In early August, the U.S. Food and Drug Administration and Health Canada said they were studying the cardiac impact of Prilosec and Nexium.

The agencies at the time cited two studies suggesting an association with greater risk of heart attacks, heart failure and heart-related sudden death when compared with surgery. However, the FDA's own initial analyses did not show a higher heart risk, and both agencies told doctors not to change prescribing practices.

The FDA, which regulates the world's biggest drug market, said it would give more definitive advice in three months. An agency spokeswoman declined to comment.

The "early communication" is part of a new FDA effort to notify the public and doctors sooner about potential drug risks. It comes after criticism of a slow response in dealing with Merck & Co's now-recalled Vioxx painkiller and safety fears tied to GlaxoSmithKline's Avandia treatment for diabetes.

Nexium is AstraZeneca's top-selling product and was the world's No. 2 best-selling drug in the world in 2006, according to pharmaceutical information firm IMS Health. AstraZeneca reported $5.2 billion in Nexium sales for last year.

The company and Procter & Gamble Co, which sells over-the-counter Prilosec, have said they agreed with the FDA's early assessment of no risk.

"These patients have two common problems: a need for (a Prilosec-type drug), and heart disease," said Dr. Michael Weinstein, who is on the board of the American Gastroenterology Association. "Both are very common, and the fact that they occasionally occur together is not surprising."

Weinstein, a gastroenterologist in private practice in Washington, is waiting for peer-reviewed proof of a link before he changes his prescription habits.

"The fact that there may be some association does not mean cause," he added. "I think that is the way most of us look at these kinds of reports."

The FDA has said both studies in question may have been skewed, in part because surgical patients tended to be younger and less likely to have risk factors for heart problems.

Fourteen other studies of patients treated for up to two years did not suggest a higher risk of heart problems with Prilosec, the FDA said.

Nexium and Prilosec are proton pump inhibitors that reduce the amount of acid produced by the stomach. Both are sold by prescription to treat acid reflux and ulcers. Prilosec also is sold over the counter for frequent heartburn.

Merck shares profits from the drugs.

More than 1 billion patients have taken the drugs, AstraZeneca said. Prilosec is known generically as omeprazole, and Nexium is known as esomeprazole.

Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

 
 
 
Google
Web www.iconocast.com

Search inside Iconocast for the keyword you have in mind.

Iconocast has collected more than 50,000 articles and press releases on health and science.

These are current and most up to date press releases on the subject you are searching.

We collect current health and science press releases daily from more than 5000 research and health institutes. Here is an example : The elderberry way to perfect skin

We believe if you do search inside Iconocast, you will get better results than searching the web alone.

 
 
Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services.

 

Iconocast Home Page

Contact Iconocast

© 2003-07. ICONOCAST is a trademark of iconocast.com.